Dimed SA Distribuidora de Medicamentos (BSP:PNVL3)

Q3 2024 Dimed SA Distribuidora de Medicamentos Earnings Call Transcript

Nov 14, 2024 / 12:30 PM GMT

Release Date Price: R$9.75 (-1.02%)

Transcript

Key Points

Positve

Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) reported a substantial sales revenue growth of 17% in Q3 2024, significantly outpacing the industry.
The company's adjusted EBITDA margin increased by 5.4%, reaching 71.8 million Rayis, with adjusted profit exceeding 37 million, up by over 37%.
Dimed SA's digital operations set it apart, with over 21% of sales occurring via digital channels, and 49% of deliveries made in under 60 minutes.
The company achieved a 1% market share in Sao Paulo, the largest market in Latin America, indicating successful expansion.
Dimed SA's focus on customer satisfaction is reflected in a high Net Promoter Score (NPS) of 78, making it the best-rated pharmacy network in its region.

Negative

The company's gross margin experienced slight pressure, decreasing from 30% to 29.9%, due to an increased share of drug sales.
There was a temporary decrease in private label product sales due to inventory disruptions caused by floods affecting their Unipar Lab.
Dimed SA faced challenges in logistics and supply chain costs due to the floods, impacting their operational leverage.
The company is experiencing a decrease in wholesale sales, which will continue to have a low share in operations moving forward.
Despite strong performance, the company acknowledges the competitive pressure from both local and national players in the pharma retail market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PNVL3.SA - Dimed SA Distribuidora De Medicamentos
Q3 2024 Dimed SA Distribuidora de Medicamentos Earnings Call
Nov 14, 2024 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. Ladies and gentlemen, welcome to the PVEL Group's Q3 2024 earnings conference.

This conference is being recorded and will be available for replay at the company's IR website where the respective slide deck can also be downloaded.

Please be advised that during the company's presentation, all participants will be connected in A&D mode.

A question and answer session will be held right after that and further instructions will be provided note also that the conference is being interpreted into English and brazilian sign language. You can select your preferred language by clicking on the interpretation button on Zoom.

No, before moving on, we'd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.